In this study, we demonstrate that PD-1+ IFN-γ+ subset of CD8+ T cells in the peripheral blood at baseline can predict response and PFS to anti–PD-1 therapy combined with chemotherapy in patients with NSCLC. This evidence concerns the gene IFNG and non-small cell lung carcinoma.